Bellerophon Therapeutics (BLPH) Files $69M IPO

Bellerophon Therapeutics (NASDAQ: BLPH) filed with the U.S. SEC for an IPO of its common stock. The proposed maximum offering price is $69 million. The company has applied to list its shares on NASDAQ under the symbol "BLPH"

Leerink Partners and Cowen and Company are the book-running managers.

Bellerophon Therapeutics is a clinical-stage therapeutics company focused on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. The company has two programs in advanced clinical development. The first program, INOpulse, is based on their proprietary pulsatile nitric oxide delivery device. They are currently developing two product candidates under the INOpulse program: one for the treatment of pulmonary arterial hypertension, or PAH, for which they intend to commence Phase 3 clinical trials in the second half of 2015, and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease, or PH-COPD, which is in Phase 2 development. The second program is bioabsorbable cardiac matrix, or BCM, which is currently in a placebo-controlled clinical trial designed to support CE mark registration in the European Union. The company completed enrollment of this trial in December 2014, with 303 patients having completed the treatment procedure, and expect to report top line results in mid-2015. Assuming positive results, they intend to conduct a pivotal pre-market approval trial of BCM beginning in the first half of 2016, which will be designed to support registration in the United States. They are developing BCM for the prevention of cardiac remodeling, which often leads to congestive heart failure following an ST-segment elevated myocardial infarction, or STEMI.

Link to S-1

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Phio Pharmaceuticals Corp. (PHIO) Reports Intratumoral Injection of PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
• Neo-Concept International Group Holdings (NCI) Prices 2.32M Share IPO at $4/sh